Skip to main content

Compare Stocks

Date Range: 

 KalVista PharmaceuticalsEvelo BiosciencesRelmada TherapeuticsEagle PharmaceuticalsSIGA Technologies
SymbolNASDAQ:KALVNASDAQ:EVLONASDAQ:RLMDNASDAQ:EGRXNASDAQ:SIGA
Price Information
Current Price$26.06$10.88$33.83$41.85$7.03
52 Week RangeBuyBuyBuyN/AN/A
MarketRank™
Overall Score1.61.61.11.00.3
Analysis Score3.53.33.30.00.0
Community Score3.02.31.42.90.0
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.81.70.0
Earnings & Valuation Score0.00.60.00.61.3
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/AN/A
Consensus Price Target$50.17$19.80$57.50N/AN/A
% Upside from Price Target92.50% upside81.99% upside69.97% upsideN/AN/A
Trade Information
Market Cap$633.47 million$580.71 million$566.55 million$548.61 million$534.74 million
Beta2.131.460.530.740.53
Average Volume821,801252,99968,565115,184263,341
Sales & Book Value
Annual Revenue$12.69 millionN/AN/A$195.89 million$26.74 million
Price / Sales49.92N/AN/A2.8020.00
CashflowN/AN/AN/A$1.52 per shareN/A
Price / CashN/AN/AN/A27.49N/A
Book Value$4.69 per share$1.88 per share$7.88 per share$13.11 per share$1.21 per share
Price / Book5.56N/AN/A3.195.81
Profitability
Net Income$-29,120,000.00$-85,470,000.00N/A$14.31 million$-7,240,000.00
EPS($1.64)($2.67)($2.16)$1.38N/A
Trailing P/E RatioN/AN/AN/A119.5717.58
Forward P/E RatioN/AN/AN/A139.50
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-229.45%N/AN/A2.65%34.62%
Return on Equity (ROE)-47.45%-159.17%-32.03%8.50%37.31%
Return on Assets (ROA)-41.84%-88.81%-31.41%5.44%25.33%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.59%N/A0.16%N/A
Current Ratio7.56%6.24%37.02%3.60%8.04%
Quick Ratio7.56%6.24%37.02%3.45%7.38%
Ownership Information
Institutional Ownership Percentage90.19%84.57%64.31%95.12%29.28%
Insider Ownership Percentage18.00%7.30%9.30%21.10%3.91%
Miscellaneous
Employees56901410642
Shares Outstanding24.31 million53.37 million16.75 million13.11 million76.07 million
Next Earnings Date7/7/2021 (Estimated)7/29/2021 (Estimated)N/A8/9/2021 (Estimated)8/5/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Siga seeks FDA approval for intravenous smallpox therapySiga seeks FDA approval for intravenous smallpox therapy
fiercepharma.com - May 11 at 12:29 PM
What Type Of Shareholders Make Up SIGA Technologies, Inc.s (NASDAQ:SIGA) Share Registry?What Type Of Shareholders Make Up SIGA Technologies, Inc.'s (NASDAQ:SIGA) Share Registry?
nasdaq.com - May 7 at 12:38 PM
SIGA Reports Financial Results for Three Months Ended March 31, 2021SIGA Reports Financial Results for Three Months Ended March 31, 2021
finance.yahoo.com - May 6 at 7:11 PM
SIGA Announces New Drug Application Filing with FDA for Intravenous Formulation of TPOXXSIGA Announces New Drug Application Filing with FDA for Intravenous Formulation of TPOXX
finance.yahoo.com - May 4 at 8:03 AM
SIGA Technologies (SIGA) Set to Announce Quarterly Earnings on ThursdaySIGA Technologies (SIGA) Set to Announce Quarterly Earnings on Thursday
americanbankingnews.com - April 30 at 11:08 AM
Mouser Electronics presenta el programa Empowering Innovation Together 2021 con un podcast debut sobre la tecnología 5GMouser Electronics presenta el programa Empowering Innovation Together 2021 con un podcast debut sobre la tecnología 5G
register-herald.com - April 29 at 9:15 AM
Mouser Electronics revela o programa Empowering Innovation Together 2021 com podcast de estreia sobre tecnologia 5GMouser Electronics revela o programa Empowering Innovation Together 2021 com podcast de estreia sobre tecnologia 5G
thedailytimes.com - April 29 at 9:15 AM
SIGA Technologies to Host Business Update Call on May 6th, 2021 Following Release of First Quarter 2021 Financial ResultsSIGA Technologies to Host Business Update Call on May 6th, 2021 Following Release of First Quarter 2021 Financial Results
finance.yahoo.com - April 29 at 9:15 AM
SIGA Technologies (NASDAQ:SIGA) Stock Price Up 3.5%SIGA Technologies (NASDAQ:SIGA) Stock Price Up 3.5%
americanbankingnews.com - April 20 at 1:40 PM
3 Buy-Rated Biotech Stocks Under $103 Buy-Rated Biotech Stocks Under $10
stocknews.com - April 19 at 1:45 PM
The 5 Best Biotech Stocks Under $20The 5 Best Biotech Stocks Under $20
investmentu.com - April 18 at 12:56 PM
Sunrise brief: Canadian Solar starts production of 665W modules based on 210mm cellsSunrise brief: Canadian Solar starts production of 665W modules based on 210mm cells
pv-magazine-usa.com - April 12 at 3:39 PM
NC K-9 officer receives body armor donationNC K-9 officer receives body armor donation
msn.com - April 12 at 12:20 AM
SIGA Technologies, Inc.s (NASDAQ:SIGA) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?SIGA Technologies, Inc.'s (NASDAQ:SIGA) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
finance.yahoo.com - April 1 at 1:36 PM
Cipla partners with SIGA Technologies to provide access to novel antibacterial drugs against biothreatsCipla partners with SIGA Technologies to provide access to novel antibacterial drugs against biothreats
indiainfoline.com - March 24 at 3:53 PM
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation ...Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation ...
apnews.com - March 24 at 5:52 AM
NATHEALTH 7th Annual Summit: Healthcare leaders to envision Indian healthcare ecosystem future in post COVID eraNATHEALTH 7th Annual Summit: Healthcare leaders to envision Indian healthcare ecosystem future in post COVID era
medicaldialogues.in - March 23 at 11:56 PM
Cipla arm partners US firm to develop novel antibioticsCipla arm partners US firm to develop novel antibiotics
livemint.com - March 23 at 8:48 AM
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreatsCipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats
finance.yahoo.com - March 23 at 8:48 AM
Cipla, SIGA Technologies join hands to provide access to novel antibacterial drugs against biothreatsCipla, SIGA Technologies join hands to provide access to novel antibacterial drugs against biothreats
medicaldialogues.in - March 23 at 4:32 AM
Cipla partners SIGA for novel antibacterial drugsCipla partners SIGA for novel antibacterial drugs
business-standard.com - March 23 at 3:47 AM
Cipla partners with SIGA Technologies to address challenge of AMRCipla partners with SIGA Technologies to address challenge of AMR
business-standard.com - March 23 at 3:47 AM
Rectangle Table Market Based on Current and Future Trends, Developments and Opportunities 2021-2026Rectangle Table Market Based on Current and Future Trends, Developments and Opportunities 2021-2026
openpr.com - March 21 at 12:06 PM
SIGA Technologies, Inc. (SIGA) CEO Phil Gomez on Q4 2020 Results - Earnings Call TranscriptSIGA Technologies, Inc. (SIGA) CEO Phil Gomez on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 7 at 12:25 AM
Edison Investment Research Lim : SIGA Technologies (SIGA): Initiation - Protection against a future pandemicEdison Investment Research Lim : SIGA Technologies (SIGA): Initiation - Protection against a future pandemic
markets.businessinsider.com - March 6 at 9:23 AM
DateCompanyBrokerageAction
3/16/2021KalVista PharmaceuticalsSVB LeerinkReiterated Rating
2/25/2021KalVista PharmaceuticalsRoth CapitalBoost Price Target
2/10/2021KalVista PharmaceuticalsHC WainwrightBoost Price Target
2/9/2021KalVista PharmaceuticalsJefferies Financial GroupBoost Price Target
2/9/2021KalVista PharmaceuticalsStifel NicolausBoost Price Target
1/26/2021KalVista PharmaceuticalsNeedham & Company LLCBoost Price Target
12/14/2018KalVista PharmaceuticalsCantor FitzgeraldReiterated Rating
5/10/2021Evelo BiosciencesMorgan StanleyLower Price Target
3/12/2021Evelo BiosciencesChardan CapitalBoost Price Target
1/25/2021Evelo BiosciencesJMP SecuritiesBoost Price Target
7/2/2020Evelo BiosciencesBMO Capital MarketsLower Price Target
2/14/2020Evelo BiosciencesCowenReiterated Rating
3/17/2021Relmada TherapeuticsOppenheimerReiterated Rating
10/28/2020Relmada TherapeuticsThe Goldman Sachs GroupDowngrade
5/4/2020Relmada TherapeuticsSunTrust BanksInitiated Coverage
12/16/2019Relmada TherapeuticsGuggenheimInitiated Coverage
3/25/2020Eagle PharmaceuticalsRoyal Bank of CanadaReiterated Rating
4/24/2019Eagle PharmaceuticalsMizuhoReiterated Rating
10/31/2018Eagle PharmaceuticalsPiper Jaffray CompaniesDowngrade
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.